Rocket Lab receives approval to acquire Mynaric in April

Rocket Lab received German approval to acquire Mynaric, with the deal expected to close in April; the company (cited value $32.6B) plans to scale Mynaric’s laser-communications production to ease supply‑chain constraints. Revenue rose 38% y/y to $601.8M and the firm reports more cash than debt; a $190M DoD contract for 20 hypersonic test flights lifts backlog to >70 launches and backlog value >$2B. A $1B equity distribution agreement and a Clear Street buy rating with an $88 PT increase capital flexibility and investor interest, though InvestingPro flags possible overvaluation after a 227% one‑year stock surge.

Analysis

Vertical integration into a critical upstream component is a force-multiplier only if execution actually reduces per-unit cost and lead time. If the acquirer can push manufacturing cadence and yield improvements, expect 200–400bps of gross-margin expansion over 12–24 months, but that requires visible throughput gains and working-capital investment before investors award multiple expansion.

The most important second-order shift is where the bottleneck migrates: moving assembly in-house simply relocates constraints to photonic subcomponents (high-power laser diodes, wavelength multiplexers, space‑grade detectors and radiation‑hardened ASICs). That creates a 6–18 month procurement advantage to incumbents who control these sub-suppliers and a procurement headache for customers who value multi-sourcing — which in turn invites competitors selling alternative link tech to pitch dual-source safety.

Regulatory and customer-concentration frictions are undervalued tail risks. Export controls, national-security reviews, or even conservative prime contractors demanding dual suppliers can blunt the pricing power from verticalizing production; those shocks are binary and can manifest quickly (weeks) when a major program decision or regulatory finding is announced, or more slowly (quarters) if quality or yield targets slip.

Consensus currently prizes strategic fit and revenue optionality; less appreciated is the near-term cash and capex profile necessary to realize scale economics and the market’s low tolerance for execution misses. That asymmetry favors option structures that capture upside from successful ramp while capping losses if ramp, certification, or customer pushback delays benefits beyond 12 months.

Key Decisions for Investors

• Long RKLB equity (size 3% NAV) — horizon 12–18 months. Rationale: capture potential margin expansion and re‑rating if production yields improve. Risk control: hard stop -25% or trim into any >40% rally. Target: 1.5x–3x return if execution milestones (quarterly visible yield/volume gains) are met.
• Buy a 12-month RKLB call spread to express asymmetric upside — buy 1x 12‑month 30% OTM call, sell 1x 12‑month 80% OTM call, position size = 1.5% NAV. Max loss = premium; payoff if market discounts integration risk. Good cost-efficient trade versus outright long.
• Hedge execution/dilution risk with puts — buy 9‑12 month RKLB 20% OTM puts sized to cover 50% of the equity notional. Use this if you take the equity position and want to limit tail risk from regulatory or customer setbacks. Breakeven: protects large drawdowns at modest premium cost.
• Event-trigger tactical: if there is an announced multi-customer supply contract or independent yield report within 6 months, add to equity up to 5% NAV; if any major prime issues dual-sourcing requests or a regulatory restriction appears, close longs and rely on puts/call spreads to harvest remaining optionality.